Dragonfly Energy Holdings has seen its fair value estimate leap from $1.88 to $18.75 per share, even as the discount rate guiding that valuation has nudged higher from 11.53% to 12.50% and revenue ...

Abstract: Rain streaks in outdoor images can severely affect the performance of high-level vision tasks, such as surveillance and autonomous driving, by obscuring important image details. The ...

Duplicates of crystal structures are flooding databases, implicating repositories hosting organic, inorganic, and ...

Abstract: Nowadays, as the demand for accurate object detection (OD) applications is increasing, several attempts have been made to introduce convolutional neural network (CNN)-based super-resolution ...

The following slide deck was published by Recursion Pharmaceuticals, Inc. in conjunction with this event.

Additionally, Recursion shared promising results from its ongoing Phase 1b/2 TUPELO trial for the drug REC-4881, showing significant polyp reduction in patients with familial adenomatous polyposis.

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Investing.com -- Recursion Pharmaceuticals (NASDAQ:RXRX) stock rose 7% Monday following positive Phase 2 trial results for its experimental drug REC-4881 in familial adenomatous polyposis (FAP), a ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...